Phase 2 Depression and Anxiety Trial, Recruiting NCT06512220 Sponsor: Centre for Addiction and Mental Health Condition: Depression and Anxiety
Back to Depression And Anxiety

Phase 2 Depression and Anxiety Trial, Recruiting

NCT06512220
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 65 years old
  • You are able to make your own informed decisions and agree to take part in the study
  • You are able to read and communicate in English well enough to understand the consent forms and questionnaires
  • You have been diagnosed with major depressive disorder (MDD) without psychosis, based on a formal clinical interview
  • Your depression has not improved after trying two or more antidepressant medications at the right dose and for long enough, and your current depression symptoms score above a certain level on a standard scale
  • You are able to swallow oral (pill-form) medication
  • If you are capable of becoming pregnant, you have been using highly effective birth control for at least 3 months before screening and agree to continue during the study
  • You are willing and medically able (confirmed by your doctor) to gradually stop taking current antidepressant or antipsychotic medications for at least 2 weeks before the study begins
  • You agree to follow the lifestyle guidelines required throughout the study

Who may not be able to join:

  • You are currently pregnant, planning to become pregnant during the study, or are breastfeeding
  • You have taken part in another clinical trial or received an experimental treatment within the past 30 days
  • You have started a new course of psychotherapy (talk therapy) within the past 12 weeks
  • You have been diagnosed with a substance use disorder (not including tobacco) within the past 6 months
  • You are currently experiencing active thoughts of suicide with a specific intent and plan
  • You have ever been diagnosed with certain serious mental health conditions, including schizophrenia, bipolar disorder (type I or II), obsessive-compulsive disorder, certain personality disorders, or significant memory/thinking disorders
  • A close blood relative (parent, sibling, or child) has been diagnosed with schizophrenia, a psychotic disorder, or bipolar I disorder
  • You have a medical reason why you cannot safely take psilocybin, such as a drug allergy to it, a recent stroke, uncontrolled high blood pressure, unstable blood pressure, a recent heart attack, irregular heart rhythm, severe heart disease, or significant kidney or liver problems
  • You have a specific heart rhythm problem called prolonged QTc or Torsade de Pointes, or a history of related heart conditions, as seen on a heart tracing (ECG)
  • You have a known allergy or medical reason why you cannot take risperidone (a medication used in the study)
  • You have a history of traumatic brain injury or any neurological or brain-related condition
  • You are unable or unwilling to have PET or MRI scans — for example, due to claustrophobia or having a pacemaker
  • You have a blood clotting disorder or are currently taking blood-thinning medication
  • You have a disability that would prevent you from completing study requirements — for example, not being able to lie still in a scanner for 1–2 hours
  • You have already reached a safe yearly or lifetime limit for radiation exposure (confirm with trial site)
  • You have another significant physical health condition that, in the opinion of the study doctor, could affect the study results or put your health at risk

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 30 June 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Centre for Addiction and Mental Health
Registry
ClinicalTrials.gov
Start date
21 April 2025
Est. completion
1 April 2027

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Feasibility of obtaining PET imaging scans before and after administration of psilocybin (25 mg) with and without risperidone (1 mg) in adults with TRD.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov